7
Jun, 2016
The 1st patient was screened in SMILE in Spain
We are happy to announce that the first patient was screened in SMILE in Spain. We encourage all the sites to follow.
7
Jun, 2016
We are happy to announce that the first patient was screened in SMILE in Spain. We encourage all the sites to follow.
1
Jun, 2016
Author: Butler K, Inshaw J, Ford D, et al. Published in: Health Technol Assess. 2016;20(49):1-108. Background For human immunodeficiency virus (HIV)-infected adolescents facing lifelong antiretroviral therapy (ART), short-cycle therapy (SCT) with long-acting agents offers the potential for drug-free weekends, less toxicity, better adherence and cost savings. Objectives To determine whether or not efavirenz (EFV)-based ART in short cycles of 5 days on and 2 days off is as efficacious (in maintaining virological suppression) as continuous EFV-based ART (continuous therapy; CT). Secondary objectives included the occurrence of new clinical HIV events or death, changes in […]
1
Jun, 2016
Author: The BREATHER (PENTA 16) Trial Group Published in: Lancet HIV. 2016;3(9):e421-430 Background For HIV-1-infected young people facing lifelong antiretroviral therapy (ART), short cycle therapy with long-acting drugs offers potential for drug-free weekends, less toxicity, and better quality-of-life. We aimed to compare short cycle therapy (5 days on, 2 days off ART) versus continuous therapy (continuous ART). Methods In this open-label, non-inferiority trial (BREATHER), eligible participants were aged 8–24 years, were stable on first-line efavirenz with two nucleoside reverse transcriptase inhibitors, and had HIV-1 RNA viral load less than 50 copies per mL for […]
